Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

A short-term intervention trial on HIV positive patients using a Sri Lankan classical rasayana drug - Ranahamsa Rasayanaya.

Somarathna KI, Chandola HM, Ravishankar B, Pandya KN, Attanayake AM.

Ayu. 2010 Apr;31(2):197-204. doi: 10.4103/0974-8520.72393.

2.

Evaluation of immunomodulatory effect of Ranahamsa Rasayanaya - A Sri Lankan classical rasayana drug, on experimental animals.

Somarathna KI, Chandola HM, Ravishankar B, Pandya KN, Attanayake AM, Ashok BK.

Ayu. 2010 Oct;31(4):495-9. doi: 10.4103/0974-8520.82040.

3.

Evaluation of adaptogenic and anti-stress effects of Ranahamsa Rasayanaya-A Sri Lankan classical Rasayana drug on experimental animals.

Somarathna KI, Chandola HM, Ravishankar B, Pandya KN, Attanayake AM, Ashok BK.

Ayu. 2010 Jan;31(1):88-92. doi: 10.4103/0974-8520.68201.

4.

Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).

Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, Frank I, Mildvan D, Mahon LF, Schock B; AIDS Clinical Trials Group 248 Study Team..

J Acquir Immune Defic Syndr. 2004 May 1;36(1):576-87.

PMID:
15097300
5.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
6.

Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.

Sánchez-Ramón S, Bellón JM, Resino S, Cantó-Nogués C, Gurbindo D, Ramos JT, Muñoz-Fernández MA.

Pediatrics. 2003 Feb;111(2):E168-75.

PMID:
12563091
7.

Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.

Gerna G, Piccinini G, Genini E, Percivalle E, Zavattoni M, Lilleri D, Testa L, Comolli G, Maserati R, Baldanti F, Maccario R, Monforte AD, Revello MG.

J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):320-31.

PMID:
11707667
8.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
9.
10.

HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.

Zaccarelli-Filho CA, Ono E, Machado DM, Brunialti M, Succi RC, Salomão R, Kallás EG, de Moraes-Pinto MI.

Cytometry B Clin Cytom. 2007 Jan 15;72(1):14-21.

11.
12.

Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy.

Benito JM, López M, Lozano S, Ballesteros C, Martinez P, González-Lahoz J, Soriano V.

J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):373-81.

PMID:
15764953
13.

Association of T cell dysfunction with the presence of IgG autoantibodies on CD4+ lymphocytes in haemophilia patients; results of a 10-year study.

Daniel V, Süsal C, Weimer R, Zipperle S, Kröpelin M, Zimmermann R, Huth-Kühne A, Opelz G.

Clin Exp Immunol. 1996 Apr;104(1):4-10.

14.

[Dynamics of T lymphocyte subsets in HAART treated AIDS patients with successful suppression of HIV replication and different CD4 + T cell restoration].

Qiu ZF, Li TS, Ruan GR, Han Y, Xie J, Zuo LY, Li YL, Wang AX.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006 Jun;28(3):386-90. Chinese.

15.

Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial.

Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M.

Ann Intern Med. 2003 Aug 19;139(4):258-66.

PMID:
12965981
16.

Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.

García F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, Fumero E, Martínez E, Mallolas J, Blanco JL, Miró JM, Pumarola T, Gallart T, Gatell JM.

J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):702-13.

PMID:
15167289
17.

Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082.

Katlama C, Carcelain G, Duvivier C, Chouquet C, Tubiana R, De Sa M, Zagury L, Calvez V, Autran B, Costagliola D; ILSTIM..

AIDS. 2002 Oct 18;16(15):2027-34.

PMID:
12370501
18.

Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients.

Clerici M, Seminari E, Maggiolo F, Pan A, Migliorino M, Trabattoni D, Castelli F, Suter F, Fusi ML, Minoli L, Carosi G, Maserati R; Master Group..

AIDS. 2002 Sep 6;16(13):1767-73.

PMID:
12218388
19.
20.

Effect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function.

Jacobson MA, Khayam-Bashi H, Martin JN, Black D, Ng V.

J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):472-7.

PMID:
12473834

Supplemental Content

Support Center